InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore
InnoCare Pharma announced today that HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority of Singapore for the treatment of adult patients with relapsed or refractory marginal zone lymphoma .
September 8, 2025
by PharmaSources
InnoCare Announces First Patient Dosed in the Registrational Trial of BCL2 Inhibitor Mesutoclax for Treatment of BTKi-treated MCL Patients in China
InnoCare Pharma announced today that the first patient has been dosed in the registrational trial of B-cell lymphoma-2 (BCL2) inhibitor mesutoclax (ICP-248) for patients with BTK inhibitor treated mantle cell lymphoma (MCL) in China.
August 21, 2025
by PharmaSources
JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma
JW Therapeutics (HKEx: 2126) announced that CDE of China's NMPA granted Breakthrough Therapy Designation for its Carteyva® (relmacabtagene autoleucel injection) in treating relapsed or refractory large B - cell lymphoma in adults.
January 13, 2025
by PR Newswire
InnoCare Announces Inclusion of Orelabrutinib’s New Indication in China National Reimbursement Drug List 2023
InnoCare Pharma announced today the inclusion of new indication of BTK inhibitor orelabrutinib in the updated National Reimbursement Drug List 2023.
December 14, 2023
by PharmaSources
With the BGB-16673 Clinical Trials of BeiGene Launched, PROTAC Leads a Brand New Trend of Global Competition
On February 28, BGB-16673, a BTK-targeted PROTAC drug of BeiGene, was launched for clinical trials for the first time in China.
March 21, 2022
by PharmaSources/Wanghong
Overall, Night Shift Work Not Tied to Higher Lymphoma Risk
Night shift work may increase the risk for chronic lymphocytic leukemia (CLL), according to a study published online...
January 24, 2022
by drugs.com
Antengene Presents Results of Phase 1b TOUCH Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics...
December 15, 2021
by prnasia
Press Release Seagen Announces Preliminary Results from Phase 2 Clinical Trial of ADCETRIS (brentuximab vedotin) in Novel Combination of Agents for Patients with Advanced Stage Classical Hodgkin Lymph
Frontline Treatment with ADCETRIS in Combination with Nivolumab, Doxorubicin and Dacarbazine (AN+AD) Shows a Complete Response Rate of 88%, Overall Response Rate of 93% and Favorable Safety Profile.
December 13, 2021
by FirstWordPharma
Secura Bio Announces Copiktra (duvelisib) Strategic Focus On T-cell Lymphoma And Voluntary U.S. Withdrawal Of The Relapsed Or Refractory Follicular Lymphoma Indication
Secura Bio, Inc. (Secura Bio) - (www.securabio.com), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies...
December 8, 2021
by Drugs
Ledaga recommended by NICE for rare type of lymphoma
The National Institute for Health and Care Excellence (NICE) has recommended Recordati Rare Diseases and Helsinn Healthcare’s Ledaga for a type of lymphoma that affects the skin.
July 19, 2021
by pharmatimes
FDA Approves Accelerated Dosing in Non-Hodgkin's Lymphoma/Leukemia Clinical Trial
AVM Biotechnology, a clinical-stage company, announced FDA permission to modify its ongoing non-Hodgkin's lymphoma/leukemia clinical study.
July 14, 2021
by americanpharmaceuticalreview
Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines
Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that the Chinese ...
May 6, 2021
by prnasia